N/A N=44 Epidermal Grafting in Wound Healing
Ulcer · Skin Ulcer · Wounds and Injuries
Primary: Number of Wounds With Complete Healing — 9; 13; 16; 20 number of wounds — p=0.366
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 StrataGraft™ Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects
Third Degree Burn · Burns · Wound Infection
Primary: Percent Autograft Take on Wounds Prepared by StrataGraft™ Skin Tissue. — 97.7; 96.7 Percent Area of Autograft Take (%)
Phase 3 N=1 StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects
Skin Wound · Burns · Trauma-related Wound
Primary: Percentage of Participants Who Achieved Confirmed Complete Closure of StrataGraft Treatment Sites Without Autograft Within 12 Weeks of StrataGraft Application — 100…
Phase 3 N=52 StrataGraft® Skin Tissue Expanded Access at Specific Study Sites ( StrataCAT )
Deep Partial-thickness Burn
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 46 Participants
Phase 1 N=30 StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns
Skin Wound · Burns · Trauma-related Wound
Primary: Number of Participants With Wound Closure of the Treatment Sites at Three Months — 29; 29 Participants
N/A N=130 RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction
Full-thickness Skin Defects · Degloving Injuries · Crush Injuries
Primary: Incidence of Treatment Area Healing — 30; 34 Treatment Areas — p=.005
N/A N=32 Split Thickness Donor Site Healing With MIST Study
Burns · Trauma · Venous Ulcers
Primary: Rate of Wound Healing — 12.1; 21.3 Days
Phase 3 N=71 StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements
Burn, Thermal
Primary: Percent Area of Treatment Sites Requiring Autografting by Month 3 — 4.33; 102.10 percentage of treatment sites — p=<0.0001
N/A N=8 An Investigation to Evaluate a New Donor Site Dressing in Surgical Burn Patients
Donor Site Complication
Primary: Percentage of Participants Who Had > 95 % Epithelialization at Day 10 — 0 percentage of participants
N/A N=18 Fractional Ablative Laser Treatment for Skin Grafts
Burn Scar · Skin Graft Scar
Primary: Contracture of Scar Surface Area (Percentage of Original Area) — 97; 97 percentage
Phase 2 N=7 Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa
Epidermolysis Bullosa Dystrophica · Epidermolysis Bullosa
Primary: Number of Wounds by Healing Category Per Investigator Visual Assessment — 35; 5; 2; 28 wounds
N/A N=34 Study of Cellutome System for Treatment of Individual Lesions in EB Pts
Epidermolysis Bullosa
Primary: Percentage of Grafts Successfully Treated — 78 Percentage of grafts
Phase 2 N=1 5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts
Ectropion · Skin Neoplasms
Primary: Graft Size Change — 10 percent change in graft
N/A N=22 Autologous Regeneration of Tissue (ART) for Wound Healing
Wound of Skin
Primary: Change of Pain on Harvesting of Skin at Donor Site. — 2.6 millimeters
N/A N=30 ReCell® Combined With Meshed Skin Graft in the Treatment of Acute Burn Injuries
Burns
Primary: Number of Participants With Confirmed Treatment Area Closure of RECELL-treated Wounds Compared to Control (Non-inferiority) — 24; 22; 2; 4 Participants
N/A N=101 A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Burns
Primary: Incidence of RECELL-treated Area Closure Compared to Control at 4 Weeks (Non-inferiority) — 82; 87; 82; 83 Participants
N/A N=19 Evaluation of Opticell Ag on Split-Thickness Skin Graft Donor Sites in Adult Subjects
Split-thickness Skin Graft Donor Sites
Primary: Pain — 4.2; 2.5; 1.1 units on a scale
Phase 3 N=112 Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSG-12)
Wounds
Primary: Intra-individual Difference in Time to Wound Closure — -0.8 days — p==0.0232
N/A N=47 Nasal Septal Flap for Donor Site Reconstruction
Nasal Septum Perforation
Primary: Mean Change in Post-operative Remucosalization at the Donor Site — 47.8; 37.8; 49.7; 43.5 percentage of remucosalization
N/A N=25 A Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients.
Burn Injury · Skin Graft
Primary: Part A: Number of Participants With Healing — 3; 21; 2; 22 Participants
Phase 3 N=107 Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSH-12)
Wounds
Primary: Intra-individual Difference in Time to Wound Closure — -1.4 days — p=<0.0001
Phase 1 N=45 Effect of Platelet Rich Plasma and Keratinocyte Suspensions on Wound Healing
Skin Graft
Primary: Complete Wound Healing — 13.9; 7.2; 5.7 Days — p=0.05
Phase 4 N=43 Open, Prosp, Rand. Invest. Evaluating Pain With Mepitel One vs.Bridal Veil and Staples on Split Thickness Skin Grafts
Deep Partial Thickness Burn · Full Thickness Burns
Primary: VAS Score for Pain Before Dressing Removal — 11.0; 4.0 units on a scale
Phase 1 N=28 Study of Survival Duration for Donor Skin Cells in Skin Biopsy Wounds
Normal Female Volunteers
Primary: Identification of the Full Set of Y-chromosome Short Tandem Repeats in Each Bioopsy. — 3; 1; 0; 0 Participants
Phase 2 N=30 Clinical Study on Silk Sericin Wound Dressing for Split-thickness Skin Graft Donor Sites Treatment
Late Complication From Skin Graft · Infection of Skin Donor Site · Impaired Wound Healing
Primary: Clinical Efficacy of Wound Dressing Containing Silk Sericin for Split-thickness Skin Graft Donor Site Treatment — 12 Days
Phase 2 N=40 TWB-103 for Adult Patients With Split-Thickness Skin Graft Donor Site Wounds
Donor Site Complication
Primary: Number of Participants With Treatment-related AEs and SAEs (Including Infections and Bleeding) — 0; 0; 0; 0 Participants
Phase 4 N=74 Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain
Pain, Postoperative · Burns
Primary: A Measurement of Post Operative Pain Involving Skin Graft Donor Site Using Visual Analog Scale (VAS) Ranging 0-10, at 8 Hours Post-operatively — 3.14; 3.68; 3.67 score…
N/A N=27 Implant Placement With Simultaneous Gum Grafting
Edentulous
Primary: Soft Tissue Thickness Over the Implant — 0.6; 0.4 mm
Phase 3 N=537 Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers
Venous Leg Ulcer
Primary: Complete Healing of the Study Ulcer by Week 16. — 201; 176 participants — p=0.1030
N/A N=19 Clinical and Histological Outcomes of Allogenic Amnion Chorion Membrane in the Healing of Free Gingival Graft Donor Site
Palatal Wound
Primary: Size of Wound Area — 80; 80 micrometers (μm)